<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089621</url>
  </required_header>
  <id_info>
    <org_study_id>12865</org_study_id>
    <secondary_id>F1J-MC-HMGE</secondary_id>
    <nct_id>NCT01089621</nct_id>
  </id_info>
  <brief_title>A Study for Adolescents With Fibromyalgia Syndrome</brief_title>
  <official_title>An Open-label Feasibility Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the possibility of conducting a larger study in&#xD;
      adolescents with fibromyalgia syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Terminated due to study design changes; zero patients enrolled.&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2010</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of enrollment</measure>
    <time_frame>6 months of enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of retention</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in score from baseline to endpoint on the Pediatric Pain Questionnaire (PPQ)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score from baseline to endpoint on the Brief Pain Inventory (BPI) modified short form severity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score from baseline to endpoint on the Clinical Global Impression of Severity, overall (CGI-Severity: overall) scale</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint score of Patient Global Impression of Improvement (PGI-I) scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score from baseline to endpoint on the Functional Disability Inventory - child version (FDI-child) scale</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score from baseline to endpoint on the Functional Disability Inventory - parent version (FDI-parent) scale</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score from baseline to endpoint on the Clinical Global Impression of Severity for Mental Illness (CGI-mental illness) scale</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score from baseline to endpoint on the Children's Depression Inventory (CDI)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score from baseline to endpoint on the Multidimensional Anxiety Scale for Children (MASC)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide-Severity Rating Scale (CSSRS)</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in score from baseline to endpoint on the Pediatric Quality of Life Inventory - teen report (PedsQL)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment emergent abnormal laboratory values</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in blood pressure</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in heart rate</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in weight</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint in height</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment emergent abnormal electrocardiogram</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>30 mg to 120 mg administered orally, daily for 12 weeks</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
    <other_name>LY248686</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet criteria for juvenile primary fibromyalgia syndrome as defined by Yunus and Masi.&#xD;
&#xD;
          -  Have a score of greater than or equal to 40mm on item 3 of the Pediatric Pain&#xD;
             Questionnaire at screening and treatment baseline.&#xD;
&#xD;
          -  Female patients must have a negative pregnancy test at baseline and must agree to&#xD;
             abstain from sexual activity or use a reliable method of birth control.&#xD;
&#xD;
          -  Patients must be capable of swallowing study drug whole.&#xD;
&#xD;
          -  Patients must have venous access sufficient to allow blood sampling and be compliant&#xD;
             with blood draws as per the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical&#xD;
             trial involving an investigational drug or device, or off-label use of a drug or&#xD;
             device, or are concurrently enrolled in any other type of medical research judged not&#xD;
             to be scientifically or medically compatible with this study.&#xD;
&#xD;
          -  Have pain symptoms related to traumatic injury, past surgery, structural bone or joint&#xD;
             disease (such as osteoarthritis, bursitis, tendonitis), or regional pain syndrome that&#xD;
             will interfere with the interpretation of outcome measures.&#xD;
&#xD;
          -  Have a confirmed current or previous diagnosis of rheumatoid arthritis, inflammatory&#xD;
             arthritis, or infectious arthritis, or an autoimmune disease.&#xD;
&#xD;
          -  Have any primary Axis diagnosis OTHER than major depressive disorder (MDD) and/or&#xD;
             generalized disorder (GAD) as defined by the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders, Fourth Edition (DSM-IV), currently or within the past year. Patients&#xD;
             with specific phobias may participate in this study.&#xD;
&#xD;
          -  Have any lifetime DSM-IV Axis I diagnosis of psychosis, bipolar disorder, or&#xD;
             schizoaffective disorder.&#xD;
&#xD;
          -  Have any DSM-IV Axis II disorder which, in the judgment of the investigator, would&#xD;
             interfere with protocol compliance.&#xD;
&#xD;
          -  Have a history of substance abuse or dependence within the past year, excluding&#xD;
             nicotine and caffeine.&#xD;
&#xD;
          -  Have a positive urine drug screen for any substances of abuse or excluded medication.&#xD;
&#xD;
          -  Have a family history of 1 or more first-degree relatives (parents or siblings) with&#xD;
             diagnosed bipolar I disorder.&#xD;
&#xD;
          -  Have a significant suicide attempt within 1 year of screening or are currently at&#xD;
             suicidal risk in the opinion of the investigator.&#xD;
&#xD;
          -  Have a weight less than 20 kg at any screening phase.&#xD;
&#xD;
          -  Have initiated, stopped, or changed the type or intensity of psychotherapy within 3&#xD;
             months prior to screening.&#xD;
&#xD;
          -  Have a history of seizure disorder (other than febrile seizures).&#xD;
&#xD;
          -  Have abnormal thyroid-stimulating hormone (TSH) concentrations. Patients with&#xD;
             hypothyroidism who have been treated on a stable dose of thyroid supplement for at&#xD;
             least the past 3 months and have medically appropriate TSH concentrations, and are&#xD;
             clinically euthyroid may participate in the study.&#xD;
&#xD;
          -  Have acute liver injury or sever cirrhosis.&#xD;
&#xD;
          -  Have previously taken duloxetine.&#xD;
&#xD;
          -  Have a serious or unstable medical illness.&#xD;
&#xD;
          -  Have initiated or discontinued hormone therapy within the previous 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

